Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,848 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of renal function in high bleeding risk patients undergoing percutaneous coronary intervention: a patient-level stratified analysis from four post-approval studies.
Kuno T, Claessen B, Cao D, Chandiramani R, Guedeney P, Sorrentino S, Krucoff M, Kozuma K, Ge J, Seth A, Makkar R, Bangalore S, Bhatt DL, Angiolillo DJ, Saito S, Neumann FJ, Hermiller J, Rau V, Ruster K, Wang J, Valgimigli M, Mehran R. Kuno T, et al. Among authors: saito s. J Thromb Thrombolysis. 2021 Aug;52(2):419-428. doi: 10.1007/s11239-020-02321-2. Epub 2021 Mar 11. J Thromb Thrombolysis. 2021. PMID: 33709255
The clinical evaluation of the Endeavor zotarolimus-eluting coronary stent in Japanese patients with de novo native coronary artery lesions: primary results and 3-year follow-up of the Endeavor Japan study.
Saito S, Prpic R, Popma JJ, Alexander J, Krucoff MW; ENDEAVOR Japan Investigators. Saito S, et al. Cardiovasc Revasc Med. 2011 Sep-Oct;12(5):273-9. doi: 10.1016/j.carrev.2010.12.007. Epub 2011 Mar 1. Cardiovasc Revasc Med. 2011. PMID: 21367669 Clinical Trial.
Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the resolute zotarolimus-eluting stent: 2-year results from the prospectively pooled analysis of the international global RESOLUTE program.
Silber S, Serruys PW, Leon MB, Meredith IT, Windecker S, Neumann FJ, Belardi J, Widimsky P, Massaro J, Novack V, Yeung AC, Saito S, Mauri L. Silber S, et al. Among authors: saito s. JACC Cardiovasc Interv. 2013 Apr;6(4):357-68. doi: 10.1016/j.jcin.2012.11.006. Epub 2013 Mar 20. JACC Cardiovasc Interv. 2013. PMID: 23523454 Free article.
Performance of the resolute zotarolimus-eluting stent in small vessels.
Caputo R, Leon M, Serruys P, Neumann FJ, Yeung A, Windecker S, Belardi JA, Silber S, Meredith I, Widimský P, Saito S, Mauri L. Caputo R, et al. Among authors: saito s. Catheter Cardiovasc Interv. 2014 Jul 1;84(1):17-23. doi: 10.1002/ccd.25485. Epub 2014 Apr 7. Catheter Cardiovasc Interv. 2014. PMID: 24659581 Clinical Trial.
Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention.
Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, Takayama M, Kitagawa K, Nishikawa M, Miyazaki S, Ikeda Y, Nakamura M, Saito S; PRASFIT-Elective Investigators. Isshiki T, et al. Among authors: saito s. Circ J. 2014;78(12):2926-34. doi: 10.1253/circj.cj-14-0266. Epub 2014 Oct 21. Circ J. 2014. PMID: 25342212 Free article. Clinical Trial.
Impact of body mass index on long-term clinical outcomes after second-generation drug eluting stent implantation: Insights from the international global RESOLUTE program.
Diletti R, Garcia-Garcia HM, Bourantas C, Van Mieghem NM, van Geuns RJ, Muramatsu T, Zhang YJ, Mauri L, Belardi J, Silber S, Widimsky P, Leon M, Windecker S, Meredith I, Neumann FJ, Yeung AC, Saito S, Liu M, van Leeuwen F, Serruys PW. Diletti R, et al. Among authors: saito s. Catheter Cardiovasc Interv. 2015 May;85(6):952-8. doi: 10.1002/ccd.25828. Epub 2015 Feb 17. Catheter Cardiovasc Interv. 2015. PMID: 25689692
7,848 results